Page 114 - Read Online

Page 200 Watson et al. J Transl Genet Genom 2020;4:188-202 I http://dx.doi.org/10.20517/jtgg.2020.31

23. Legati A, Reyes A, Nasca A, Invernizzi F, Lamantea E, et al. New genes and pathomechanisms in mitochondrial disorders unraveled by
NGS technologies. Biochim Biophys Acta 2016;1857:1326-35.
24. Meienberg J, Bruggmann R, Oexle K, Matyas G. Clinical sequencing: is WGS the better WES? Hum Genet 2016;135:359-62.
25. Belkadi A, Bolze A, Itan Y, Cobat A, Vincent QB, et al. Whole-genome sequencing is more powerful than whole-exome sequencing for
detecting exome variants. Proc Natl Acad Sci U S A 2015;112:5473-8.
26. Puttick C, Kumar KR, Davis RL, Pinese M, Thomas DM, et al. A highly sensitive mitochondrial variant analysis pipeline for whole
genome sequencing data. bioRxiv 2019:852210.
27. Ernster L, Ikkos D, Luft R. Enzymic activities of human skeletal muscle mitochondria: a tool in clinical metabolic research. Nature
1959;184:1851-4.
28. Luft R, Ikkos D, Palmieri G, Ernster L, Afzelius B. A case of severe hypermetabolism of nonthyroid origin with a defect in the
maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J Clin Invest 1962;41:1776-
804.
29. Engel WK, Cunningham GG. Rapid examination of muscle tissue. an improved trichrome method for fresh-frozen biopsy sections.
Neurology 1963;13:919-23.
30. Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike
episodes: a distinctive clinical syndrome. Ann Neurol 1984;16:481-8.
31. Fukuhara N, Tokiguchi S, Shirakawa K, Tsubaki T. Myoclonus epilepsy associated with ragged-red fibres (mitochondrial abnormalities):
disease entity or a syndrome? Light-and electron-microscopic studies of two cases and review of literature. J Neurol Sci 1980;47:117-33.
32. Schon EA, Hirano M, DiMauro S. Mitochondrial encephalomyopathies: clinical and molecular analysis. J Bioenerg Biomembr
1994;26:291-9.
33. Bernier FP, Boneh A, Dennett X, Chow CW, Cleary MA, et al. Diagnostic criteria for respiratory chain disorders in adults and children.
Neurology 2002;59:1406-11.
34. Naviaux RK. Developing a systematic approach to the diagnosis and classification of mitochondrial disease. Mitochondrion 2004;4:351-61.
35. Hirano M, Ricci E, Koenigsberger MR, Defendini R, Pavlakis SG, et al. Melas: an original case and clinical criteria for diagnosis.
Neuromuscul Disord 1992;2:125-35.
36. DiMauro S, Garone C. Historical perspective on mitochondrial medicine. Dev Disabil Res Rev 2010;16:106-13.
37. Koenig MK. Presentation and diagnosis of mitochondrial disorders in children. Pediatr Neurol 2008;38:305-13.
38. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, et al. Sequence and organization of the human mitochondrial genome.
Nature 1981;290:457-65.
39. Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, et al. Mitochondrial DNA mutation associated with Leber’s hereditary optic
neuropathy. Science 1988;242:1427-30.
40. Holt IJ, Harding AE, Morgan-Hughes JA. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature
1988;331:717-9.
41. Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial
encephalomyopathies. Nature 1990;348:651-3.
42. McCormick E, Place E, Falk MJ. Molecular genetic testing for mitochondrial disease: from one generation to the next. Neurotherapeutics
2013;10:251-61.
43. Calvo SE, Clauser KR, Mootha VK. MitoCarta2.0: an updated inventory of mammalian mitochondrial proteins. Nucleic Acids Res
2016;44:D1251-7.
44. Frazier AE, Thorburn DR, Compton AG. Mitochondrial energy generation disorders: genes, mechanisms, and clues to pathology. J Biol
Chem 2019;294:5386-95.
45. Craven L, Alston CL, Taylor RW, Turnbull DM. Recent advances in mitochondrial disease. Annu Rev Genomics Hum Genet
2017;18:257-75.
46. Rahman S. Mitochondrial disease in children. J Intern Med 2020; doi: 10.1111/joim.13054.
47. Zeviani M, Bresolin N, Gellera C, Bordoni A, Pannacci M, et al. Nucleus-driven multiple large-scale deletions of the human
mitochondrial genome: a new autosomal dominant disease. Am J Hum Genet 1990;47:904-14.
48. Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, et al. Mutation of a nuclear succinate dehydrogenase gene results in
mitochondrial respiratory chain deficiency. Nat Genet 1995;11:144-9.
49. Goto Y. Clinical features of MELAS and mitochondrial DNA mutations. Muscle Nerve Suppl 1995;3:S107-12.
50. Chin J, Marotta R, Chiotis M, Allan EH, Collins SJ. Detection rates and phenotypic spectrum of m.3243A>G in the MT-TL1 gene: a
molecular diagnostic laboratory perspective. Mitochondrion 2014;17:34-41.
51. Nesbitt V, Pitceathly RD, Turnbull DM, Taylor RW, Sweeney MG, et al. The UK MRC Mitochondrial Disease Patient Cohort Study:
clinical phenotypes associated with the m.3243A>G mutation--implications for diagnosis and management. J Neurol Neurosurg
Psychiatry 2013;84:936-8.
52. Lake NJ, Compton AG, Rahman S, Thorburn DR. Leigh syndrome: one disorder, more than 75 monogenic causes. Ann Neurol
2016;79:190-203.
53. Neveling K, Feenstra I, Gilissen C, Hoefsloot LH, Kamsteeg EJ, et al. A Post-Hoc comparison of the utility of sanger sequencing and
exome sequencing for the diagnosis of heterogeneous diseases. Hum Mutat 2013;34:1721-6.
54. Wortmann SB, Mayr JA, Nuoffer JM, Prokisch H, Sperl W. A guideline for the diagnosis of pediatric mitochondrial disease: the value of
muscle and skin biopsies in the genetics era. Neuropediatrics 2017;48:309-14.